Prescribe14 launches.
$9.2B in cumulative
peak-year revenue.
One strategist.
From Phase III data package to formulary placement — the commercialization infrastructure that turns clinical proof into market share.
Formulary Win Rate
across 47 payer submissions
Payer strategy built around the P&T committee's actual objections — not the ones you wish they had.
Most payer decks fail before the second slide. The committee has read three submissions this week that sound exactly like yours. Prescribe reverse-engineers the clinical and economic arguments that survive real-world P&T scrutiny — mapping ICER thresholds, head-to-head data gaps, and budget impact models to the specific formulary tier you're targeting. The outcome isn't a deck. It's a decision architecture.
FDA Advisory Committee prep that accounts for the panel member who already has a position before you speak.
Advisory committee outcomes are shaped in the 90 days before the meeting, not the day of. Prescribe builds the briefing book, the pre-meeting scientific exchange strategy, and the response matrix for the three questions that will define the vote. Clients arrive knowing exactly which panel members need which data — and how to deliver it without triggering the perception of overreach.
Avg. Timeline Compression
from NDA submission to advisory committee readiness
Every week without a payer strategy is a week the formulary decision defaults to your competitor.
A single strategic session clarifies the submission architecture, the payer narrative, and the launch sequencing before the first dollar of commercial spend is committed.
Request a Confidential BriefingThe gap between clinical proof and commercial success is not a science problem. It is a strategy problem. And strategy problems have precise solutions.
Cumulative Peak-Year Revenue
across 14 launched products
Launch sequencing that captures peak share before the generic filing lands.
Patent cliffs are not surprises. The window between first commercial sale and biosimilar entry is a known quantity — and every quarter of sub-optimal share capture is permanent revenue loss. Prescribe builds launch sequencing models that front-load payer access, KOL activation, and field force deployment into the 18-month window that defines a product's commercial ceiling. Fourteen launches. Zero that left peak share on the table.
Lifecycle management strategy that makes the patent cliff a planning assumption, not a crisis.
The conversation most pharma leadership teams avoid until Q3 of the loss-of-exclusivity year is the one Prescribe opens in Phase III. Indication sequencing, combination therapy positioning, line extension regulatory strategy, and BD&L target identification — built into a single lifecycle model that gives the CFO a defensible revenue curve and gives the commercial team a roadmap that doesn't require reinvention every 18 months.
Portfolio IRR Improvement
median across lifecycle management engagements
Is this engagement relevant to you?
Therapeutic area and deal stage coverage — mapped to the specific commercial inflection points where strategic clarity has the highest leverage.
Solid tumors, hematologic malignancies, IO combinations
Ultra-orphan pricing, CMS coverage strategy, patient services infrastructure
ASCVD outcomes data, guideline positioning, PCP pull-through
Endpoint negotiation, patient-reported outcomes, label strategy
Switching friction models, payer contract architecture, KOL mapping
Real-world evidence strategy, HEOR model design, payer narrative
Accelerated approval pathway, post-market commitment strategy
Specialty pharmacy access, co-pay architecture, hub services
The window between Phase III readout and first commercial sale closes faster than your team thinks.
A confidential briefing takes 45 minutes. The commercialization roadmap it produces has a shelf life measured in quarters, not weeks.
Request a Confidential BriefingNo form. No intake questionnaire. One click carries intent.